Dublin, July 30, 2018 (GLOBE NEWSWIRE) -- The "Nuclear Medicine/Radiopharmaceuticals Global Market - Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The global nuclear medicine/radiopharmaceutical market is expected to reach $9,275.3 million by 2022

Over the past 50 years nuclear medicine sector has displayed a strong link between investments in chemistry and development of radionuclide's and radiolabeled compounds. This advancement has majorly impacted the health care practice. In the present scenario nuclear medicine is considered to be one of the diagnostics and therapeutic modality technique for probing, tracking and treating disease-related tissue function, progression and treatment response.

Non-invasive nuclear medicine imaging technique provides functional information at both molecular and cellular level and helps measuring the uptake and turnover of target-specific radiotracers in tissue.

Radioisotopes are used in a wide variety of applications like oncology, cardiovascular and neurological disorders. But in recent times, advancements in the field of nuclear medicine and radioactive tracers have emerged to provide few practical methods for studying the limited metabolic activities of bones and teeth, hence has found a role in dental science research.

Nuclear medicinal market is mainly classified into type (diagnosis & therapeutics), application and end-users. The global nuclear medicine market by diagnosis is further divided into SPECT and PET while therapeutics market is segmented into alpha radiation therapy, beta radiation therapy and brachytherapy.

The nuclear medicine/radiopharmaceuticals market is expected to grow at single digit CAGR during 2015 to 2022. The factors driving the growth of this market are increased application of radiopharmaceuticals, rise in public awareness, usage of hybrid imaging, abundance of radio pharmaceuticals, technological advancements; alpha radio immunotherapy based targeted cancer treatment and wide range of available products likely to propel the nuclear medicine market.

In addition to this, increasing need in emerging markets, production of radio pharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes, increasing therapeutic application areas and replacement of old/traditional equipment are some of the opportunities that are propelling the growth of the market. However, regulatory issues, high cost and supply shortage of isotopes, shorter half life of radiopharmaceuticals, and threat from traditional/alternative diagnostic procedures are hampering the growth of the market.

The threats for the nuclear medicine/radiopharmaceuticals market include huge capital investment and shortage of qualified technicians. The major problem area of nuclear medicine market is closure of reactors.

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Take Aways
2.2 Report Scope
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
3.3.1.1 Increased Applications Of Radiopharmaceuticals
3.3.1.2 Rise In Public Awareness
3.3.1.3 Usage Of Hybrid Imaging
3.3.1.4 Technological Advancements
3.3.1.5 Increasing Needs In Emerging Markets
3.3.1.6 Production Of Radiopharmaceuticals From Cyclotrons
3.3.1.7 Efficient Diagnosis And Treatments
3.3.2 Restraints And Threats
3.3.2.1 Shorter Half-Life Of Radiopharmaceuticals
3.3.2.2 High Cost And Supply Shortage Of Isotopes
3.3.2.3 Radio Toxicity
3.3.2.4 Shortage Of Qualified Technicians
3.3.2.5 Regulatory Issues
3.3.2.6 Threat From Traditional/Alternative Diagnostic Procedures
3.3.2.7 Huge Capital Investment
3.4 Problem Areas
3.4.1 Closure Of Reactors
3.5 Winning Imperatives
3.5.1 Availability Of Technetium
3.6 Regulatory Guidelines
3.7 Reimbursement Scenario And Challenges
3.8 Clinical Trials
3.9 Patent Trends
3.10 Supply Chain Analysis
3.10.1 Reactors
3.10.2 Processing Facility
3.10.3 Generators Manufacturing Units
3.10.4 Hospitals And Central Radio Pharmacies
3.11 List Of Potential New Reactors
3.12 List Of FDA Approved Radiopharmaceuticals
3.13 Porter's Five Force Analysis
3.13.1 Threat Of New Entrants
3.13.2 Threat Of Substitutes
3.13.3 Bargaining Power Of Suppliers
3.13.4 Bargaining Power Of Buyers
3.13.5 Competitive Rivalry
3.14 Market Share Analysis By Major Players
3.14.1 Nuclear Medicine Market
3.14.2 Spect Market
3.14.3 Pet Market
3.14.4 Tc-99 Market

4 Nuclear Medicine Global Market, By Modality
4.1 Introduction
4.2 Diagnostics
4.2.1 Radiopharmaceuticals For Diagnosis, By Isotopes
4.2.1.1 Spect, By Isotopes
4.2.1.1.1 Technetium (Tc-99M)
4.2.1.1.2 Thallium (Tl-201)
4.2.1.1.3 Gallium (Ga-67)
4.2.1.1.4 Iodine (I-123)
4.2.1.1.5 Samarium (Sm-153)
4.2.1.1.6 Yttrium (Y-90)
4.2.1.1.7 Rhenium (Re-186)
4.2.1.1.8 Others
4.2.1.2 Pet, By Isotopes
4.2.1.2.1 Fluorodeoxyglucose (18F-Fdg)
4.2.1.2.2 Gallium (Ga-68)
4.2.1.2.3 Rubidium (Rb-82)
4.2.1.2.4 Others
4.2.2 Nuclear Medicine For Diagnosis, By Application
4.2.2.1 Spect By Application
4.2.2.1.1 Cardiology
4.2.2.1.2 Pulmonary
4.2.2.1.3 Oncology
4.2.2.1.4 Nephrology
4.2.2.1.5 Neurology
4.2.2.1.6 Inflammation
4.2.2.1.7 Thyroid Glands
4.2.2.1.8 Lymphology
4.2.2.1.9 Others
4.2.2.2 Pet By Application
4.2.2.2.1 Oncology
4.2.2.2.2 Neurology
4.2.2.2.3 Cardiology
4.2.2.2.4 Inflammation
4.2.2.2.5 Others
4.3 Therapeutics
4.3.1 Nuclear Medicine For Therapeutics, By Radiation Type
4.3.1.1 Beta Radiation Therapy
4.3.1.1.1 Yttrium (Y-90)
4.3.1.1.2 Iodine (I-131)
4.3.1.1.3 Lutetium (Lu-177)
4.3.1.1.4 Samarium (Sm-153)
4.3.1.1.5 Rhenium (Re-186)
4.3.1.1.6 Strontium (Sr-89)
4.3.1.1.7 Erbium (Er-169)
4.3.1.1.8 Others
4.3.1.2 Alpha Radiation Therapy, By Isotopes
4.3.1.3 Brachytherapy, By Isotopes
4.3.1.3.1 Iodine (I-125)
4.3.1.3.2 Cesium (Cs-131)
4.3.1.3.3 Iridium (Ir-192)
4.3.1.3.4 Palladium (Pd-103)
4.3.1.3.5 Others
4.3.2 Nuclear Medicine Therapeutics, By Application
4.3.2.1 Prostate Cancer
4.3.2.2 Thyroid Cancer
4.3.2.3 Liver Cancer
4.3.2.4 Gep-Net Therapeutics
4.3.2.5 Metastatic Bone Cancer Therapeutics
4.3.2.6 Breast Cancer Therapeutics
4.3.2.7 Other Therapeutic Applications

5 Nuclear Medicine Global Market, By End-Users
5.1 Introduction
5.2 Hospital
5.3 Ambulator-Y Centers
5.4 Diagnostic Centers
5.5 Other End-Users

6 Stable Isotopes
6.1 Introduction
6.2 Market Analysis
6.2.1 Factors Influencing Market
6.2.2 Drivers And Opportunities
6.2.2.1 Increase In Research Activities (Pharmaceuticals And Biotechnology Sectors)
6.2.2.2 Increasing Applications
6.2.3 Restraints And Threats
6.2.3.1 High Cost Of Stable Isotopes
6.2.3.2 Stable Isotopes-Side Effects And Safety Issues
6.2.3.3 Stringent Regulations For Manufacturing And Use Of Stable Isotopes
6.3 Stable Isotopes Market, By Isotope
6.3.1 Carbon (C-13)
6.3.2 Deuterium (D2)
6.3.3 Oxygen (O-18)
6.3.4 Nitrogen (N-15)
6.3.5 Sulphur (S-32)
6.3.6 Others
6.4 Stable Isotopes Market, By Application
6.4.1 Introduction
6.4.2 Diagnostics And Therapy
6.4.3 Pharmaceuticals
6.4.4 Others
6.5 Stable Isotopes Market, By Geography
6.5.1 Introduction
6.5.2 North America
6.5.3 Europe
6.5.4 Asia-Pacific
6.5.5 Rest Of The World

7 Regional Analysis

8 Competitive Landscape
8.1 Introduction
8.2 Approvals And Agreements
8.3 Acquisition, Expansion And Collaboration
8.4 Others Developments

9 Major Player Profiles

• Ablynx Nv
• Abx Gmbh
• Actinium Pharmaceuticals, Inc
• Advanced Accelerator Applications
• Advanced Medical Isotope Corporation
• Affibody Ab
• Algeta Asa
• Aptuit
• Areva Med
• Arronax
• Auspex Pharmaceuticals
• Bard Medicals
• Bavarian Nordic
• Bayer Healthcare
• Best Medical International, Inc
• Bio Analytical Research Corporation Laboratories
• Bio-Nucleonics,Inc
• Bracco Diagnostics Incs
• Btg International Ltd
• Bv Cyclotron Vu
• Cambridge Isotope Laboratories Inc.
• Cardinal Health Inc.
• Cellectar Biosciences
• Centre For Probe Development And Commercialization
• China Isotope Corporation
• Clarity'S Pharmaceuticals
• Coqui Pharmaceuticals
• Cortecnet
• Cp Medical
• Digirad Corporation
• Draximage Inc.
• Eckert & Ziegler Strahlen
• Eden Radioisotopes Llc
• Eli Lilly & Co
• Eurisotop
• Fujifilm Corporation
• Ge Healthcare
• Huayi Isotopes Co
• Iba Group
• Ibt-Bebig
• Idb Holland Bv
• Immunomedics
• Industrial Nuclear Company
• International Isotopes Inc.
• Invap S.E
• Iso Ray Medical Inc
• Iso Therapeutics Group, Llc
• Iso-Analytical Ltd
• Isoaid Llc
• Isoflex Isotope
• Isorad Ltd
• Isotec Inc
• Isotope Technologies Garching
• Ithemba Labs
• Joint Stock Company Isotope
• Lantheus Medical Imaging Inc
• Linde Group
• Mallinckrodt Plc
• Medi-Physics, Inc
• Medical Isotopes, Inc
• Mediso Medical Imaging Systems
• Memorial Sloan Kettering Cancer Center
• Navidea Biopharmaceuticals Inc
• Nihon Medi Physics Co Ltd
• Nordion Inc.
• Northstar Medical Technologies
• Ntp Radioisotopes Soc Ltd
• Octreopharm Sciences Gmbh
• Ostuka Pharmaceuticals Co Ltd
• Pars Isotope
• Peregrine Pharmaceuticals, Inc
• Perkin Elmer
• Perma-Fix Medical Sa
• Petnet Solution
• Philips Health Care
• Positron Corporation
• Radiomedix, Inc.
• Rotem Medical
• Royal Philips Electronics
• Sanofi
• Sercon Australia Pvt Ltd
• Sercon Ltd
• Shangai Research Institute Of Chemical Industry
• Shine Medical Technologies, Inc
• Siemens Healthcare
• Sievert
• Sirtex
• Source Production And Equipment Company+F191
• Spectrum Pharmaceuticals, Inc
• Spepharm Ag
• Stb Isotope Germany Gmbh
• Sterigenics International
• Steripet
• Tayyo Nippon Sanso Corporation
• Theragenics Corporation
• Thermo Fisher Scientific
• Toshiba Medical Systems Corporation
• Tracerco
• Trigon Biotechnology Inc
• Urenco
• Westinghouse Electric Company
• Zevacor Molecular

For more information about this report visit https://www.researchandmarkets.com/research/8h92qd/9_27_billion?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.